Work

The R&D Boundaries of the Firm: An Empirical Analysis

Year: 1990
Type: preprint
Abstract: Investigates the decisions of large, established pharmaceutical companies to develop new biotechnology-based pharmaceutical products with in-house research and development (RD (2) are more likely to internalize RD (3) that tended to use in-house RD (4) are more likely to undertake a biotechnology RD and (5) with a higher percentage of their business in pharmaceuticals will be more likely to internalize biotechnology-pharmaceutical R&D projects. Data were gathered from the fifty largest pharmaceutical companies in the world on R&D project-level procurement decisions. Findings indicate that small-numbers-bargaining hazards in the R&D markets do motivate the internalization of R&D. However, it was found that rivalry among established pharmaceutical firms does not lead to internalization. Also supported is the notion that firm-level factors influence R&D procurement patterns, but a firm's history in regard to technological procurement was not a significant indicator of its behavior in new technology. Finally, size was not found to be a significant factor in procurement decisions. (SFL)
Institution: Harvard University
Language: English
Open Access status: green
OpenAlex ID: W3122618869
Cites:
Cited by: 172
Related to: 9